Immortagen, Inc., a Coralville, Iowa-based women’s cancer company, completed a Series A equity financing.
The amount of the deal was not disclosed.
The company will use the funds to continue to develop its prototype artificial intelligence-based algorithms.
Launched in 2014 by University of Iowa researchers Donghai Dai, MD, PhD, MS, Kristina Thiel, PhD, Baoli Yang, MD, PhD and Kimberly Leslie, MD, and led by Led by President & CEO Kurt F. Heiar, Immortagen is developing genetic analysis tools, which will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.
The company, which was selected as the University of Iowa Start Up of the Year for 2016, previously received funding from the Iowa Economic Development Authority and the University of Iowa GAP Commercialization Fund.